Latest News and Press Releases

NEW YORK, March 06, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (NASDAQ: SEEL), a clinical-stage biopharmaceutical company, announced today that they will webcast their presentation at the...

NEW YORK, March 01, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, announced today that they will participate in the 39th Annual Cowen...

Diversifies Seelos’ pipeline in rare diseases Collaborates with Team Sanfilippo Foundation in development of Trehalose in Sanfilippo syndrome NEW YORK, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Seelos...

NEW YORK, Jan. 24, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to...

SAN DIEGO, Jan. 15, 2019 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq: APRI) has today reported that it obtained stockholder approval as required pursuant to the terms of the merger...

SAN DIEGO, Dec. 14, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq: APRI) has today convened and adjourned its special meeting of stockholders in order to obtain specific stockholder...

Seeking Shareholder Approval for Proposed Merger with Seelos Therapeutics, Inc. SAN DIEGO, Dec. 10, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq: APRI), a biopharmaceutical company...

Company Merger with Seelos Therapeutics, Inc. Expected to Close in Fourth Quarter 2018 Apricus Shareholders Expected to Own ~15% of Estimated $94 Million Combined Company Valuation at Closing ...

Company Enters Into Merger Agreement with Seelos Therapeutics, Inc. Apricus Shareholders Expected to Own ~14% of Combined Company Based on Estimated $90 Million Valuation at Closing Merger Expected...

Transaction to result in Nasdaq-listed company focused on developing novel products to treat central nervous system diseasesTransaction expected to advance Seelos’ robust, late-stage pipeline of five...